Ascletis Submits IND Application to the U.S. FDA for ASC36_37o FDC, a Potentially First-in-Class Once-Weekly Oral Quadruple Peptide Agonist Targeting Amylin Receptor, GLP-1R, GIPR and GCGR, for the Treatment of Obesity

Wait 5 sec.

- ASC36_37o FDC is a potential first-in-class, once-weekly oral pill candidate targeting all four validated obesity targets. - ASC36_37o FDC supports once-weekly oral dosing, as demonstrated in non-human primates, with half-lives of up to 200 hours (approximately 8.3 days) for ASC36 and...